Hoʻoulu ʻo GMP-TL778 Anti-Human CD137 mAb i ka hoʻonui ʻana o ka cell T a me ka huna ʻana o ka cytokine

ʻO 4-1BB, ka mea i kapa ʻia ʻo CD137, he inducible cell surface receptor a hoʻokahi lālā o ka tumor necrosis factor receptor (tumor necrosis factor receptor, TNFR) superfamily. Hoʻopili ʻia ʻo CD137 e ke ʻano o ka ʻōpū necrosis factor receptor superfamily member 9 (TNFRSF9) a hōʻike nui ʻia ma ka ʻili o nā pūnaewele T i hoʻōla ʻia a me nā pūnaewele NK. ʻO kona ligand, CD137L, he lālā TNFSF hoʻi, he mea hoʻokipa costimulatory inducible i hōʻike ʻia e ka CD4 + a me nā CD8 + T cell, NKT, NK cell, DC, macrophages, eosinophils, neutrophils a me nā mast cell, ʻoi aku ma luna o nā pūnaewele CD8 + T. Hoʻopili ʻo CD137 / CD137L i nā pane kūlohelohe ma o ka hoʻouna ʻana i nā hōʻailona hoʻōla, hoʻonui, a i ʻole apoptotic ma waena o nā cell immune. Hiki i ka ho'ā ʻana o CD137 ke hoʻoulu i ka cell NK a me T cell proliferation a hoʻoulu i ka hana anti-tumor, kahi e hoʻoulu ai i nā pane hoʻomanaʻo lōʻihi. Hiki iā 4-1BB mAb ke hoʻoikaika i ka 4-1BB e kiʻi i nā mea pili TNFR TRAF1 a me TRAF2. A laila, hana ʻo TRAF1 a me TRAF2 i heterotrimer, e hoʻoikaika ana i ka lawe ʻana i ka hōʻailona ma o ke ala c-Jun N terminal kinase (JNK) a i ʻole extracellular signal-regulated kinase (ERK). Hiki i kēia heterotrimer ke hoʻoulu i ka hoʻonuiʻana o nā pūnaewele T a me nā pūnaewele hōʻike antigen, e hoʻonui i ka pane kū'ē kū'ē kū'ē o ke kino a hūnā i nā cytokines ma o ka transcription o NF-κB.